Zanubrutinib demonstrated a 5-year progression-free survival (PFS) rate of 72.2% and overall survival rate of 85.1% in patients with deletion of the 17p chromosome (del[17p]) chronic lymphocytic ...
MicroRNAs are endogenous regulatory RNAs of approximately 22 nucleotides that fine-tune gene expression by promoting mRNA degradation or inhibiting translation. In chronic lymphocytic leukaemia (CLL), ...
BTK and PLCG2 mutations are prevalent in patients with CLL treated with BTKi, but other resistance mechanisms may exist. BTK/PLCG2 mutational profiles have not yet proven useful in guiding subsequent ...
Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results